Kombination eines Bispezifischen Antikörperkonstrukts, eines Immuncheckpoint-Inhibitors und eines Taxans

Details

Veröffentlichungs-Nr.

EP4751731

Anmeldetag

29. November 2024

Veröffentlichung

3. Juni 2026

Rechtsraum

EP

Abstract

The invention relates to a bispecific antibody construct, a taxane, and/or an immune checkpoint inhibitor for use in a method of treating a tumor in a subject, wherein the bispecific antibody construct comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR, wherein the method comprises administering to the subject the bispecific antibody construct, the taxane, and the immune checkpoint inhibitor. The invention further relates to a composition comprising a taxane and a bispecific antibody construct that comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR.

Anmelder

Firma

Affimed GmbH

Land

🇩🇪 Deutschland